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Abstract
Background: Chronic inflammation has been suggested to favour prostate cancer (PCA) development. Interleukins
(IL) represent essential inflammation mediators. IL-2, IL-7, IL-15 and IL-21, sharing a common receptor g chain (c-g),
control T lymphocyte homeostasis and proliferation and play major roles in regulating cancer-immune system
interactions. We evaluated local IL-2, IL-7, IL-15 and IL-21 gene expression in prostate tissues from patients with
early stage PCA or benign prostatic hyperplasia (BPH). As control, we used IL-6 gene, encoding an IL involved in
PCA progression. IL-6, IL-7 and IL-15 titres were also measured in patients’ sera.
Methods: Eighty patients with BPH and 79 with early (1 to 2c) stage PCA were enrolled. Gene expression in
prostate tissues was analyzed by quantitative real-time PCR (qRT-PCR). Serum IL concentrations and acute phase
protein titres were evaluated by ELISA. Mann-Whitney, Wilcoxon and c
2 tests were used to compare IL gene
expression and serum titers in the two groups of patients. Receiver operating characteristic (ROC) curves were
constructed to evaluate the possibility to distinguish sera from different groups of patients based on IL titers.
Results: IL-2 and IL-21 gene expression was comparably detectable, with low frequency and at low extents, in PCA
and BPH tissues. In contrast, IL-6, IL-7 and IL-15 genes were expressed more frequently (p < 0.0001, p = 0.0047 and
p = 0.0085, respectively) and to significantly higher extents (p = 0.0051, p = 0.0310 and p = 0.0205, respectively) in
early stage PCA than in BPH tissues. Corresponding proteins could be detected to significantly higher amounts in
sera from patients with localized PCA, than in those from patients with BPH (p = 0.0153, p = 0.0174 and p =
0.0064, respectively). Analysis of ROC curves indicates that IL-7 (p = 0.0039), but not IL-6 (p = 0.2938) or IL-15 (p =
0.1804) titres were able to distinguish sera from patients with malignancy from those from patients with benign
disease. Serum titres of C reactive (CRP), high mobility group B1 (HMGB1) and serum amyloid A (SAA) acute phase
proteins were similar in both groups of patients.
Conclusions: Expression IL-7 and IL-15 genes in prostate tissues and corresponding serum titres are significantly
increased in patients with early stage PCA as compared with patients with BPH.
Background
Prostate cancer (PCA) is the second leading cause of
cancer-related death in men with a death rate reaching
26.7% for 2001-2005 in United States[1]. Chronic
inflammation has been suggested to play a major role in
prostate oncogenesis[2]. Furthermore, local and systemic
immunosuppression have also been reported in patients
bearing PCA[3-6]. The clarification of molecular
mechanisms underlying these phenomena might provide
novel insights into PCA induction and progression, of
potentially high clinical relevance.
Cytokines represent key mediators of inflammation
and play pivotal roles in the interaction between
immune system and cancer. A number of them have
been suggested to be associated with advanced stage
PCA[7]. IL-4 and, in particular, IL-6 have been shown
to exert antiapoptotic effects on PCA cells, whereas
proangiogenic effects of IL-8 have been demonstrated
[7].
A group of lymphokines including, among others, IL-
2, IL-7, IL-15 and IL-21 share a receptor g-chain[8].
Common receptor g-chain (c- g) cytokines regulate
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CD8+ T cell homeostatic proliferation and functions
[13,14]. IL-2, IL-7, IL-15 and IL-21 are of particular
interest in cancer immunotherapy[15]. Importantly, IL-2
is FDA approved for the treatment of melanoma and
renal cell carcinoma, whereas IL-7 has been used with
promising results in phase I/II trials in clinical oncology
[16,17]. IL-15 has not yet been used in clinical trials.
However, experimental models and “in vitro” evidence
suggest that it may represent a cancer treatment with
high potential clinical relevance[18-20]. Finally, IL-21
has been shown in murine models to prevent T lympho-
cyte exhaustion induced by chronic stimulation[21-23].
In phase I/II clinical trials, IL-21 has also shown repro-
ducible antitumor effects[24,25].
Notably, however, elevated IL-7 serum levels have
been detected in Hodgkin disease and in ovarian cancers
[26-29]. Furthermore, IL-7 has been shown to be pro-
duced by breast and colorectal cancer cells[30,31]. IL-15
has also been shown to be produced by colon cancer
cells and specific gene expression has been shown to be
associated with distant metastases [32]. Moreover, ele-
vated IL-15 serum levels were detected in multiple mye-
loma[33].
Little is known about IL-2, IL-7, IL-15 and IL-21 gene
expression and protein secretion in patients bearing
PCA or BPH. Indeed, IL-2 gene expression and IL-15
protein have been detected in BPH tissues[34,35].
Furthermore, IL-7 gene has been found to be expressed
in PCA tissues[36,37] and the corresponding protein has
been detected in patients’ s e r a .H o w e v e r ,n oc o m p a r a -
tive analysis in patients with BPH and PCA has been
performed so far and no data are currently available for
IL-21 expression in PCA and BPH.
In order to evaluate the potential role of these IL in
early phases of prostate oncogenesis, in this study we
have evaluated the expression of specific genes in pro-
static tissues from patients bearing either localized pT1-
2c PCA or BPH and we have measured the titres of cir-
culating proteins in their sera.
Our results indicate that in prostatic tissues from
patients bearing early stage PCA, the expression of IL-7
and IL-15 genes is significantly enhanced, as compared
to BPH, while no significant differences could be
observed in IL-2 or IL-21 gene expression. Accordingly,
titres of circulating IL-7 and IL-15 are increased in
patients with localized PCA, as compared to patients
with BPH. Most interestingly, IL-7 titres might help to
discriminate sera from patients with PCA or BPH.
Patients and methods
Patients
We investigated a consecutive series of 159 specimens
from men diagnosed for BPH or PCA at the
Department of Urology of the University Hospital of
Basel (Switzerland) from 2007 to 2010. Patients with
BPH underwent conventional transurethral resection
(TUR-P), while patients with PCA underwent either pal-
liative TUR-P or endoscopic extraperitoneal radical
prostatectomy (EERP). Relevant clinical data were col-
lected by reviewing patients’ files.
Written informed consent was obtained from patients
in accordance with the requirements of the Ethical
Committee of Basel (EKBB, Ref.Nr. EK: 176/07).
Quantification of gene expression in prostatic tissues by
quantitative Real-Time PCR
Prostatic tissues were screened for the presence of
tumors by an experienced pathologist (L. Bubendorf).
Total RNA was extracted by using RNeasy
® MiniKit
(Qiagen, Basel, Switzerland), deoxyribonuclease I (Invi-
trogen, Carlsbad, California) treated and reverse tran-
scribed by using M-MLV Reverse Transcriptase
(Invitrogen, Carlsbad, California). Quantitative RT-PCR
was performed using the TaqMan
® Universal PCR Mas-
ter Mix (Applied Biosystems, Forster City, CA), and the
following primers and probes:
GAPDH[38]
Fwd ATGGGGAAGGTGAAGGTCG
Rev TAAAAGCAGCCCTGGTGACC
Probe FAM-CGCCCAATACGACCAAATCCGTT-
GAC-TAMRA
IL-2[39]
Fwd AACTCACCAGGATGCTCACATTTA
Rev TCCCTGGGTCTTAAGTGAAAGTTT
Probe FAM-TTTTACATGCCCAAGAAGGCCACA-
GAACT-TAMRA
IL-6[40]
Fwd CAGCCCTGAGAAAGGAGACATG
Rev GGTTCAGGTTGTTTTCTGCCA
Probe FAM-AGTAACATGTGTGAAAGCAGCAAA-
GAGGCAC-TAMRA
IL-21, IL-7 and IL-15 primers and probes were pro-
vided by Assays-on-Demand, Gene Expression Products
(Applied Biosystems, Forster City, CA).
Specific gene expression was quantified by using the 2
-
ΔΔC
T method[41]. Normalization of gene expression was
performed using GAPDH as reference gene.
ELISA assays
Commercial ELISA kits for IL-6, IL-7 and IL-15 were
obtained from Pharmingen (San Diego, CA). Detection
limit was 1pg/ml for all assays. HMGB1 ELISA kit was
obtained from Shino-Test Corporation (Kanagawa,
Japan). SAA and CRP ELISA kits were obtained from
USB (Swampscott, MA) and Roche Diagnostics Cobas
®
(Mannheim, Germany), respectively. Detection limits
were 1 ng/ml, 0.6 ng/ml, and 0.6 μg/ml, for HMGB1,
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in accordance to the instructions from the producers.
Statistical Analysis
Mann-Whitney tests were used to compare mean
expression of cytokine genes and cytokine serum titers
for independent samples while Wilcoxon test was used
for paired samples. When n ≥ 30, Student’sT - T e s t s
were used to compare means. Frequencies of specific
gene expression in two groups were assessed by c
2 tests.
Differences with p < 0.05 were considered significant.
Receiver operating characteristic (ROC) curves were cre-
ated to verify whether cytokine titers could be used to
distinguish patients with PCA from patients with BPH
[27].
Results
Clinico-pathological profiles of the patients
A group including 79 patients (average age ± SEM =
64.3 ± 0.8) undergoing surgical treatment for localized
stage 1-2 PCA and a group of 80 patients (average age
± SEM = 68.1 ± 0.9) undergoing surgical treatment for
BPH were enrolled in the study. Of the 79 PCA patients,
2 (2.6%) were diagnosed with stage pT1, 2 (2.6%) with
stage pT1a, 1 (1.3%) with stage pT1b, 3 (3.8%) with
stage pT2, 13 (16.4%) with stage pT2a, 4 (5%) with stage
pT2b, 54 (68.3%) with stage pT2c.
Average serum Prostate Specific Antigen (PSA) ± SEM
in PCA patients was 8.26 ± 1.46 ng/ml (n = 74) and
average Gleason score ± SEM was 6.63 ± 0.10 (n = 78).
Average serum PSA value ± SEM in BPH patients was
5.49 ± 0.87 ng/ml (n = 63).
Expression of c-g cytokines genes in prostatic tissues
In the initial phase of our study, we quantitatively ana-
lyzed IL-2, IL-7, IL-15 and IL-21 gene expression in a
series of tissue samples from localized PCA and BPH.
As shown in figure 1, IL-2 gene expression was detect-
able in 20/32 (62.5%) and in 37/49 (75.5%) BPH and
PCA specimens, respectively (p = 0.2099). Under a
quantitative view point, comparably low levels of expres-
s i o nc o u l db eo b s e r v e di nB P Ha n dP C At i s s u e s( p=
0.1721).
In contrast, IL-7 gene expression was significantly more
frequently observed in PCA than in BPH specimens [29/
34 (85.3%) and 51/51 (100%) BPH and PCA, respectively
(p = 0.0047)]. IL-15 gene was also expressed more fre-
quently in PCA than in BPH samples [16/31 (51.6%) and
39/49 (79.6%) BPH and PCA specimens, respectively (p =
0.0085)]. Notably, under a quantitative point of view, IL-
7 and IL-15 gene expression was also significantly
increased in tissues from patients bearing early stage
PCA as compared to those from patients with BPH (p =
0.0310 and p = 0.0205, respectively, figure 1).
IL-21 gene expression was relatively rarely detectable
in prostatic tissues from patients bearing BPH or stage
pT1-2c PCA [3/26 (11.5%) and 4/47 (8.5%) BPH and
PCA tissues, respectively (p = 0.6739)]. Furthermore, the
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Figure 1 Expression of IL genes in early stage PCA and BPH tissues. Total cellular RNA was extracted from BPH and PCA tissues, DNAse
treated, reverse transcribed and analyzed by quantitative real-time PCR for IL-2 (BPH: n = 32, PCA: n = 49), IL-7 (BPH: n = 34, PCA: n = 51), IL-15
(BPH: n = 31, PCA: n = 49), IL-6 (BPH: n = 60, PCA: n = 54) and IL-21 (BPH: n = 26, PCA: n = 47) specific gene expression. Data are expressed as
ratio to GAPDH gene expression. Mean values (▬) are indicated for each group. Digits in individual panels indicate percentages of samples
displaying gene expression levels exceeding detection limits (bold, bottom of the panel) and statistical significance of differential extent of
specific gene expression in BPH or PCA specimens (top of the panel).
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the two groups (p = 0.6040, figure 1).
IL-6 is known to be a mediator of PCA morbidity, and
may act as a cell growth factor and protect cancer cells
from death[42]. Therefore, we used the expression of
this gene as control of the integrity of our assays.
Indeed, IL-6 gene expression was detected in 29/60
(48.3%) and in 46/54 (85.2%) BPH and early stage PCA
specimens, respectively (p < 0.0001). Under a quantita-
tive point of view, IL-6 gene expression was also signifi-
cantly increased in tissues from patients bearing PCA as
compared to BPH (p = 0.0051), thus confirming our
previous findings[43].
Taken together these data indicate that although genes
encoding the c-g cytokines under investigation may be
expressed in BPH tissues, IL-7 and IL-15 genes are
expressed to a significantly higher extent in localized
PCA.
IL-6 gene was previously found to be expressed by
prostate cancer cells[44]. To address the issue of the
nature of the cell types possibly expressing other cyto-
kine genes in PCA tissues, we evaluated IL-2, IL-7, IL-
15 and IL-21 gene expression in PC3, DU145 and
LNCaP established PCA cell lines. Interestingly, we
found that all cell lines expressed IL-15 gene, whereas
IL-6 and IL-7 genes were only expressed in PC3 and
DU145 cells (figure 2). In contrast, IL-2 and IL-21 genes
were not expressed by any of the cell lines under
investigation.
Detection of c-g cytokines in sera from patients with early
stage PCA
High IL-6 serum titres have been observed in advanced
PCA [42]. Furthermore, increased IL-7 serum titres have
been reported in PCA[37], as compared to non age
matched healthy donors, but no comparison with sera
from patients with BPH was attempted, nor were
patients with early stage PCA specifically studied. In
order to verify, at the systemic level our findings from
BPH and localized PCA tissues, we comparatively evalu-
ated circulating titres of IL-6, IL-7 and IL-15 in pre-
operative sera from patients with prostatic diseases.
IL-6 was highly significantly increased even in sera
from patients with pT1-2c stage PCA, as compared to
sera from patients with BPH (average IL-6 concentration
±S E M=5 7 . 3 4±1 2 . 1 2v s .2 7 . 4 6±2 . 6 2p g / m l ,p=
0.0153, figure 3A.1.). Most interestingly, serum levels of
IL-7 and IL-15 were also significantly higher in patients
with localized PCA as compared to patients with BPH
(average IL-7 concentration ± SEM = 32.69 ± 9.73 vs.
5 . 8 7±1 . 1 7p g / m l ,p=0 . 0 1 7 4a n da v e r a g eI L - 1 5c o n -
centration ± SEM 208.07 ± 48.50 vs. 50.51 ± 14.34 pg/
ml, p = 0.0064, figure 3A.1.). Remarkably, a highly sig-
nificant correlation was observed between IL-7 and IL-
15 levels in sera from patients with either early stage
PCA (p < 0.0001, R = 0.6631, n = 50) or BPH (p <
0.0001, R = 0.6019, n = 40) (Figure 3, panels A.2. and
A.3.).
Notably, cytokine serum titres did not significantly
correlate with the specific expression of the correspond-
ing gene in autologous prostate tissues.
IL-7 serum titres distinguish patients with BPH or PCA
ROC curves were constructed to verify whether serum IL
titres could help distinguishing patients with localized
PCA from patients with BPH (Figure 3B). Interestingly,
although specific serum titres were significantly higher in
patients with PCA, as compared with patients with BPH,
areas under curve (AUC) were small for IL-6 (AUC:
0.5547, 95%CI: 0.4515-0.6579) and IL-15 (AUC: 0.5825,
95%CI: 0.4647-0.7003). Therefore, these cytokine titres
were not helpful in identifying patients with early stage
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Figure 2 Expression of IL genes in PCA cell lines Total RNA was extracted from three PCA cell lines: PC-3 DU-145 and LNCaP. Following
DNase treatment, RNA were reverse transcribed and resulting cDNA were analysed by quantitative real-time PCR for IL-2, IL-7, IL-15, IL-6 and IL-
21 specific gene expression. Data are expressed as ratio to GAPDH gene expression.
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Page 4 of 9malignancies (p = 0.2938 and p = 0.1804, respectively). In
contrast, analysis of the ROC curve for IL-7 (AUC: 0.6775,
95%CI: 0.5676-0.7874 p = 0.0039) indicated that specific
IL titres were effectively distinguishing patients with early
stage PCA from patients with BPH.
Detection of acute phase proteins in sera from patients
with early stage PCA
Serum biomarkers of systemic inflammation C reactive
protein (CRP) and serum amyloid A (SAA), have been
f o u n dt ob ea s s o c i a t e dw i t hP C A[ 4 5 - 4 7 ] .F u r t h e r m o r e ,
HMGB1 gene has been suggested to be overexpressed
in prostate PCA [48]. The corresponding gene product
is a prominent member of a group of mediators released
by damaged cells, collectively known as damage asso-
ciated molecular patterns (DAMP)[49]. These factors
might be responsible for the activation of the innate
immune system, potentially resulting in cytokine gene
expression and secretion[50].
We did not observe significant differences between
sera from patients with early stage PCA and those from
patients with BPH regarding CRP, SAA or HMGB1
levels (Table 1: average CRP concentration ± SEM 7.47
±1 . 9 2μg/ml vs. 5.70 ± 1.16 μg/ml, p = 0.4370; average
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Figure 3 Circulating levels of soluble factors in serum from patients bearing early stage PCA or BPH A. Sera from patients bearing BPH
or PCA were collected prior to surgery and tested for their content in the indicated factors by ELISA (A.1.). Statistical significance of differential
titers in sera from patients bearing either BPH or PCA is also reported. Correlations between IL-7 and IL-15 levels in sera from patients with early
stage PCA (A.2.) or BPH (A.3.) are displayed. B. ROC curves were created for all IL under investigation and their ability to distinguish between sera
of patients with PCA or BPH was analyzed.
Table 1 Acute phase protein concentrations in sera from
patients with early stage PCA and BPH
CRP
(μg/ml)
SAA
(μg/ml)
HMGB1
(ng/ml)
Early stage PCA Average 7.47 2.81 52.77
SEM 1.92 0.31 12.48
n 66 18 18
BPH Average 5.70 2.71 49.11
SEM 1.16 0.29 15.13
n 66 19 19
p 0.4370 0.7728 0.7497
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μg/ml, p = 0.7728; average HMGB1 concentration ±
SEM 52.77 ± 12.48 vs. 49.11 ± 15.13 ng/ml, p = 0.7497).
Notably, no significant correlation could be observed
between IL-6, IL-7 or IL-15 serum levels and acute
phase protein titres. Similarly, no correlation with PSA
levels or Gleason score was detectable.
Discussion
A large body of literature based on histopathological,
epidemiological and molecular pathology data suggests
that chronic inflammation might play an important role
in prostate oncogenesis [2]. IL represent essential med-
iators of inflammation and titres of a number of them
have been shown to be increased in patients bearing
PCA[7]. Most of these studies, however, have addressed
IL detection in patients with advanced stage cancers. In
these conditions, high tumor burdens and mechanisms
inherent with metastatic spread, e,g, osteolysis, might be
involved in the induction of IL production. Furthermore,
sterile inflammation primed by intratumoral ischemia
and associated necrosis could also promote IL release
[51]. Therefore, data from patients with advanced
tumors are unlikely to provide useful information on the
role eventually played by inflammation or immunosup-
pression in prostate oncogenesis. In order to gain
insights into events occurring in early stages of prostate
cancerogenesis, in this study we evaluated IL gene
expression and protein production at local and systemic
levels, respectively, in localized PCA, as compared with
BPH.
Our data clearly indicate that the expression of a
number of genes encoding pro-inflammatory and
homeostatic IL, including IL-6, IL-7 and IL-15 is detect-
able more frequently and to a higher extent, in early
stage PCA as compared to BPH tissues. Notably, the
genes encoding these IL were also found to be expressed
to different levels by established PCA cell lines.
To investigate the possibly systemic nature of the pro-
inflammatory state detectable in PCA[37,52], we mea-
sured IL titres in sera from patients with BPH or early
stage PCA. We report here for the first time that IL-7
and IL-15 serum levels are significantly higher in
patients with localized PCA than in patients with BPH.
IL-6 titres were also significantly higher in patients with
PCA than in patients with BPH despite the early stage
of their disease [53].
IL-6 is known to be produced by multiple cell types,
including activated macrophages, smooth muscle cells
and PCA cells [53]. Instead, IL-7 is produced by multi-
ple stromal cell types and epithelial cells from different
districts including thymus and gut[10]. Most recently
IL-7 production has been detected in normal, but not in
transformed prostate epithelial cells[36]. IL-15 is
typically produced by activated antigen presenting cells
of the myeloid lineage, including monocytes, macro-
phages and dendritic cells. However, IL-15 gene has also
b e e nf o u n dt ob ee x p r e s s e db yam u l t i p l i c i t yo fo t h e r
cell types, including stromal and epithelial cells[9].
Importantly, epithelial BPH cells have been shown to
express IL-15[34]. In our patients, IL serum titres were
not significantly correlated with specific gene expression
in the autologous prostate tissues, thereby suggesting
that cells other than tumor cells might be at least in
part responsible for IL production. Thus, while we here
show that IL-6, IL-7 and IL-15 genes are expressed in
established PCA cell lines, future studies are warranted
to clarify the cellular sources of these IL within the
prostate and systemically.
The nature of the mechanisms promoting IL-6, IL-7
and IL-15 gene expression and protein production in
PCA is also unclear. Different microorganisms, including
virus and bacteria[54,55] have been suspected to contri-
bute to oncogenesis in the prostate. Indeed, their pre-
sence could result in chronic inflammation.
Alternatively, it has been suggested that direct damage
of epithelial cells might be caused by toxic compounds
contained in urines or by dietary factors[2]. Cell death
might, in turn, result in the activation of the innate
immune system by DAMPs [49]. Soluble factors pro-
duced by DAMP-triggered innate immune system cells,
including IL-6, have repeatedly been suggested to pro-
mote prostate cancerogenesis[2]. However, here we
show that at least circulating levels of HMGB1, SAA
and CRP acute phase proteins are similar in patients
with BPH or localized, early stage PCA.
Analysis of ROC curves indicates that IL-7, but
neither IL-6 nor IL-15 titres do distinguish sera from
patients with PCA from sera from patients with BPH.
These findings might set the stage for larger studies also
addressing the clinical relevance of IL-7 serum titres in
the monitoring of PCA response to treatment and
recurrences.
On the other hand, our data raise the issue of potential
functional consequences of c- g cytokine gene expression
and secretion in PCA. Preliminary experiments indicate
that none of the IL under investigation enhances the pro-
liferation of cells from established PCA cell lines (data
not shown). However, studies performed in breast cancer
[56] indicate that IL-7 promotes the production of pro-
angiogenic factors by tumor cells and proliferation of
endothelial cells. IL-15 has also been shown to stimulate
angiogenesis “in vivo”[57]. Furthermore, although IL-7
and IL-15 are known to promote survival and functional
maturation of T cells, they have also been demonstrated
to induce the expression of PD-1 “exhaustion” marker in
these cells[58]. Indeed, PCA tissues have been shown to
be infiltrated by T cells largely expressing PD-1, and, less
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sistent with previous reports on the phenotypic charac-
teristics of circulating and tissue infiltrating lymphocytes
in chronic viral infections[61-64]. In this context, it is
remarkable that we found that the expression of the IL-
21 gene, that is of the gene encoding the cytokine pre-
venting PD-1 mediated T cell exhaustion[21-23] is rarely
detectable in PCA.
Conclusions
Our work indicates that even in early stages of PCA
development, genes encoding IL of pro-inflammatory
significance are over-expressed in malignant tissues, as
compared to BPH specimens, Importantly, correspond-
ing proteins are detectable to higher levels in sera from
patients with localized PCA as compared to patients
with BPH, and, in particular, IL-7 titres might represent
an additional marker of potential clinical relevance.
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